Skip to the main content

Professional paper

Peroral administartion of lomustine, chlorambucil, etopozide and prednsiolone (CCEP) for treatment of patients with advanced lymphoma

Ivo Radman ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Marijo Vodanović ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Zdravko Mitrović ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Igor Aurer ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Sandra Bašić Kinda ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Boris Labar ; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska


Full text: croatian pdf 395 Kb

page 389-395

downloads: 1.322

cite


Abstract

Aim: Treatment efficacy of CCEP (CCNU, chlorambucil, etopozide and prednisolone), the oral palliative chemotherapy was analyzed in refractory and relapsed lymphoma patients in advanced stages. Methods: In a retrospective study we analyzed 20 patients treated in our institution in 10-year interval. Eight patients were diagnosed with Hodgkin lymphoma, 9 with aggressive non-Hodgkin lymphoma and 3 with indolent lymphoma. Results: Patients receiving ≥3 cycles of CCEP achieved better response rate and longer survival. The progression of the disease was the main reason for discontinuation. Overall response rate was 50 % (10/20 patients); 6/20 patients obtained stable state and 4/20 progressive disease. Median follow-up was 11 months with 30 % of 2-year survival rate. Discussion and conclusion: CCEP is a low-cost and effective chemotherapy with acceptable toxicity and good tolerability. In half of the patients with very adverse prognosis one can expect temporary treatment success.

Keywords

CCEP; CCNU; chlorambucil; etoposide; limfom; prednisolone

Hrčak ID:

76672

URI

https://hrcak.srce.hr/76672

Publication date:

1.12.2011.

Article data in other languages: croatian

Visits: 2.295 *